Sana Biotechnology, Inc. (SANA)
Nasdaq: SANA · Biological Products, (No Diagnostic Substances) · Seattle, WA · filing with the SEC since 2020
Who owns Sana Biotechnology, Inc.
As filed with the SECHolders of 5% or more
3
Robert Nelsen holds 15.4% of Common Stock, par value $0.0001 per share, as its SCHEDULE 13G/A filed Aug 14, 2026 says.
Directors and officers
12
report now, of 21 people on the record since 2021. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 3 named at left.
Holders of 5% or moreshare of the class, as filed
Robert Nelsen
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, par value $0.0001 per share · 17.3% in Nov 14, 2025
RA Capital Management, L.P.
SCHEDULE 13G · filed May 21, 2026 · Common Stock, $0.0001 par value per share
Blackrock, Inc.
SCHEDULE 13G · filed Jan 21, 2026 · Common Stock · 4.9% in Apr 25, 2025
The Vanguard Group
SCHEDULE 13G/A · filed Jan 31, 2025 · Common Stock · reported falling below 5%
What SANA reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
Cobalt Biomedicine Inc
A company bought · acquisition · owns, named in the 10-K filed Mar 3, 2026
Insider tradesForm 4
0sales
0purchases
0sales on a scheduled plan
0people selling
$0sold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Oct 6, 2025 to Oct 6, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2024 runs to Oct 6, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window
No one on the roster filed an open-market trade in the window.